McHale Duncan's Form 4 filing
Evelo Biosciences, Inc. (EVLO) · filed Aug 9, 2023
- Accession no.
- 0001694665-23-000134
- Filed
- Aug 9, 2023
- Trade date
- Aug 7-8, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $32.7K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| McHale DuncanCIK 0001738896 | Officer (Chief Medical Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 7, 2023 | Common Stock | MOption exerciseDisposed | −6,500 | $0.00 | $0 | 13,000 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer common stock.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported in Column 4 is an average price. These shares were sold in multiple transactions at prices within the range of $9.08 to $9.55, inclusive. The reporting person undertakes to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4.
Referenced by the price of 1 transaction in Table I.
Remarks
On June 29, 2023, the Issuer effected a 1-for-20 reverse stock split. The share counts herein have been adjusted to reflect the reverse stock split.